Testosterone increases bone mineral density in female‐to‐male transsexuals: a case series of 15 subjects
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: objective Testosterone therapy for osteoporosis has not been studied extensively in women because of its potential to cause virilization. Female‐to‐male transsexuals are genetic females who suffer from gender dysphoria and thus take supra‐physiologic doses of testosterone to change from the female to male phenotype. The aim of this study is to examine the effects of testosterone treatment on the genetic female skeleton. patients and design A group of 15 female‐to‐male transsexuals was prospectively enrolled for observation over a 2‐year period. The subjects had a mean age of 37·0 ± 3·0 years. All of the subjects self‐administered testosterone esters intramuscularly at a mean dose of 70·7 ± 4·5 mg weekly. measurements The subjects had measurements of bone mineral density (BMD) by dual X‐ray absorptiometry (DXA) of the femoral neck and spine (L2–L4) at 12‐month intervals. They had determinations of serum oestradiol, testosterone, soluble RANKL (sRANKL), osteoprotegerin (OPG) and urine N‐telopeptide (NTX) at the date of enrolment and at the end of 2 years. results There was a significant positive increase in mean BMD of 7·8% at the femoral neck and a nonsignificant increase in mean BMD of 3·1% at the spine over 2 years. The levels of testosterone reached the upper normal range for males and the levels of oestradiol declined to near the postmenopausal range. sRANKL levels decreased significantly in female‐to‐male transsexuals who newly initiated testosterone therapy. There was no significant change in urine NTX or serum OPG during the study. conclusions We conclude that supra‐physiologic testosterone therapy increases BMD at the hip while maintaining BMD at the spine in female‐to‐male transsexuals. The effects of testosterone may be the result of testosterone hormone directly acting on the bone or indirectly through aromatization to oestradiol. Lower RANKL levels coupled with unchanged OPG levels results in an increased OPG/RANKL ratio, which may be beneficial to the bone by inhibiting osteoclastogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“, 1998) or oestrogen receptor (Smith et al., 1994) develop severe osteoporosis, which further supports the notion that oestradiol is the more dominant sex steroid in preserving bone density.”
BackgroundMorley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 1×
“Testosterone treatment of elderly men with hypogonadism increases BMD (Katznelson et al., 1996; Behre et al., 1997, 1999; Snyder et al., 1999; Amory et al., 2004).”
BackgroundFalahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“However, a study of elderly men rendered hypogonadal with GnRH agonists demonstrated that men receiving oestrogen had significantly lower bone turnover than men receiving testosterone (Falahati-Nini et al., 2000).”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“Several in vitro studies have demonstrated that oestrogen increases OPG levels in bone marrow stromal and osteoblastic cells (Hofbauer et al., 1999; Chen et al., 2000; Saika et al., 2001).”
BackgroundLong-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559
Khosla, S. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3555 · Cited by 522 · cited 1×
“, 2003) and is a stronger determinant of peak bone mass (Khosla et al., 2001).”
BackgroundAmory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475
Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Khosla, S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2266 · Cited by 447
Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194 · cited 1×
“Several in vitro studies have demonstrated that oestrogen increases OPG levels in bone marrow stromal and osteoblastic cells (Hofbauer et al., 1999; Chen et al., 2000; Saika et al., 2001).”
BackgroundKhosla, S., Atkinson, E. J., Dunstan, C. R., & O’Fallon, W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8397 · Cited by 191 · cited 2×
“When the same elderly men rendered hypogonadal with GnRH agonists were treated with oestrogen, there were increases in OPG (Khosla et al., 2002).”
BackgroundHofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72
Cited by
Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01658 · Cited by 2,328
“However, adequate dosing of testosterone is important to maintain bone mass in transgender males (189, 190).”
Self-citationEndocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., Spack, N. P., Tangpricha, V., & Montori, V. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0345 · Cited by 1,026
Self-citationVitamin D and neurocognitive dysfunction: Preventing “D”ecline?
Buell, J. S., & Dawson-Hughes, B. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.001 · Cited by 342
Long-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual Persons
Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, E., Roef, G., Heylens, G., & T’Sjoen, G. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02876.x · Cited by 335
Endocrinology of Transgender Medicine
T’Sjoen, G., Arcelus, J., Gooren, L., Klink, D. T., & Tangpricha, V. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00011 · Cited by 314
Self-citation
Metadata
- Authors
- Turner, A., Chen, T. C., Barber, T. W., Malabanan, A. O., Holick, M. F., & Tangpricha, V.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2004-10-12
- Volume
- 61
- Issue
- 5
- Pages
- 560-566
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2004105591
- Cited by
- 83
- References
- 13
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.